ArticleCell stem cell2019
Targeting the RNA m
Open access · bronzeAbstract read
In one paragraph
Article in Cell stem cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 327 papers.
0numbers the graph read from it
0cells of the map it votes in
327citing papers in PubMed
28.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
327 citing papers in PubMed, 546 citations in OpenAlex.
- Cell-cycle-driven noncanonical ubiquitination of METTL14 orchestrates RNA methylation.Nature chemical biology · 2026Article
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- Review
- Article
- Single-cell RNA sequencing reveals chemotherapy-induced apoptosis in acute myeloid leukemia via B cell depletion and M2 to M1 macrophage repolarization.Human genomics · 2026Article
- Emerging roles of RNA mInternational journal of oncology · 2026Review
- m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis.Cancer research communications · 2026Article
- Function and regulatory mechanism of RNA-binding protein IGF2BP2 in obesity and cancers.Molecular biology reports · 2026Review
- Reduced YTHDF2 inhibits PD-L1 expression by stabilizing mCell death & disease · 2026Article
- Elevated mBMC cancer · 2026Article
- Mechanisms and therapeutic potential of YTHDF readers: Linking epitranscriptomics to cancer.Journal of pharmaceutical analysis · 2026Review
- RBM15B recognizes H3K79me2 to guide selective mThe EMBO journal · 2026Article
- NNature reviews. Cancer · 2026Review
- Emerging role of RNA modification reader YTHDF2 in hematopoiesis, immunity, and cancer.MedScience · 2026Review
- Single-nucleotide m⁶A mapping uncovers redundant YTHDF function in planarian progenitor fate selection.The EMBO journal · 2026Article
- BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia.bioRxiv : the preprint server for biology · 2026Article
- Elevated m 6 A RNA Modifications Associate with Immune Dysregulation and Cancer in People with HIV-1.Research square · 2026Article
- Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function.The Journal of experimental medicine · 2026Article
267 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 3 countries.
Jasmin ParisMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Marcos MorganMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK; Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK.
Joana CamposMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Gary J SpencerLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4GJ, UK.
Alena ShmakovaMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Ivayla IvanovaMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK.
Christopher MapperleyMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Hannah LawsonMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
David A WotherspoonMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Catarina SepulvedaMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Milica VukovicMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Lewis AllenMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Annika SarapuuMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Andrea TavosanisLaboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Amelie V GuitartMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Arnaud VillacrecesMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK.
Christian MuchMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK.
Junho ChoeDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Ali AzarMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Louie N van de LagemaatMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Douglas VernimmenRoslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK.
Ali NehmeUniversité de Tours, CNRS, LNOx ERL 7001, Tours, France.
Frederic MazurierUniversité de Tours, CNRS, LNOx ERL 7001, Tours, France.
Tim C P SomervailleLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4GJ, UK.
Richard I GregoryDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Dónal O'CarrollMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK; Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK. Electronic address: donal.ocarroll@ed.ac.uk.
Kamil R KrancMRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Electronic address: kamil.kranc@qmul.ac.uk.
University of Edinburgh · GBMRC Centre for Regenerative Medicine · GBQueen Mary University of London · GBHarvard University · USUniversité de Tours · FRCancer Research UK Manchester Institute · GBUniversity of Manchester · GBWellcome Centre for Cell Biology · GB
Funding
Role of RNA modifications in spermatogenesis.ZIAES103339 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MORGAN, MARCOS · 2019 to 2025
$10.8MCancer Research UK 14633Cancer Research UK 19280Cancer Research UK 26787Cancer Research UK 29389Cancer Research UK C29967/A14633Cancer Research UK C29967/A26787Cancer Research UK C5759/A20971Medical Research Council MR/P010008/1Medical Research Council MR/P010008/2Wellcome TrustWellcome Trust 092076Wellcome Trust 106144
Abstract
Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem cells (HSCs) and primitive progenitors that blocks their myeloid differentiation, generating self-renewing leukemic stem cells (LSCs). Here, we show that the mRNA m
Indexed as
AnimalsCell Self RenewalHematopoiesisHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteMiceMice, Inbred C57BLMice, KnockoutNeoplastic Stem CellsRNA-Binding ProteinsRNA, Small InterferingTHP-1 CellsRNA-Binding ProteinsRNA, Small InterferingYTHDF2 protein, humanYTHDF2 protein, mouseacute myeloid leukemiahematopoiesishematopoietic stem cellleukemic stem cellsm(6)A modificationmRNA decayTNFR2YTHDF2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.